48-week changes in biomarkers in subjects with high cardiovascular risk switching from ritonavir-boosted protease inhibitors to dolutegravir: the NEAT022 study

E. Martinez, L. Assoumou, G. Moyle, L. Waters, M. Johnson, P. Domingo, J. Fox, H. Stellbrink, G. Guaraldi, M. Masia, M. Gompels, S. de Wit, E. Florence, S. Esser, F. Raffi, A. Pozniak, J. Gatell

    Research output: Contribution to journalConference abstract in journal

    Original languageEnglish
    JournalJournal of the International AIDS Society
    Number of pages2
    Publication statusPublished - 2018



    Cite this